NeuroTherapia is developing NTRX-07 (previously identified as MDA7) for the treatment of Alzheimer's disease. There is currently no effective treatment for Alzheimer's disease (AD). MDA7 offers a new approach to controlling the neuroinflammatory response observed in AD and decreasing the neuronal injury that leads to memory loss.After a decade of research, MDA7 has been shown to decrease microglial mediated neuroinflammation, a potential common pathway for several diseases. MDA7 is a Cannabinoid Receptor 2 (CB2) agonist that is distinct from previously studied compounds in its selectivity for the targeted receptor and its ability to reach the CB2 receptors in the central nervous system.MDA7 reduces inflammation and restores memory and function in models of AD.The current research is designed to study the safety and side effects of NTRX-07 in animals. The data from these studies will allow us to apply to the FDA for an Investigational New Drug application so that studies can begin in humans.